Ophthalmic artery angioplasty for age-related macular degeneration.

Autor:	Lylyk I; Department of Interventional Neuroradiology, Instituto Medico ENERI, Buenos Aires, Argentina ivan@lylyk.com.ar., Bleise C; Department of Interventional Neuroradiology, Instituto Medico ENERI, Buenos Aires, Argentina., Lylyk PN; Department of Interventional Neuroradiology, Instituto Medico ENERI, Buenos Aires, Argentina., Perez N; Department of Neuroradiology, Instituto Medico ENERI, Buenos Aires, Argentina., Lundquist J; Department of Interventional Neuroradiology, Instituto Medico ENERI, Buenos Aires, Argentina., Scrivano E; Department of Interventional Neuroradiology, Instituto Medico ENERI, Buenos Aires, Argentina., Francone AA; Department of Ophthalmology, Centro Oftalmológico Dr Daniel Charles S.A, Buenos Aires, Argentina., Charles M; Department of Ophthalmology, Centro Oftalmológico Dr Daniel Charles S.A, Buenos Aires, Argentina., Zompa T; Department of Ophthalmology, Centro Oftalmológico Dr Daniel Charles S.A, Buenos Aires, Argentina., Lylyk P; Department of Interventional Neuroradiology, Instituto Medico ENERI, Buenos Aires, Argentina.
Jazyk:	angličtina
Zdroj:	Journal of neurointerventional surgery [J Neurointerv Surg] 2022 Oct; Vol. 14 (10), pp. 968-972. Date of Electronic Publication: 2022 Jan 05.
DOI:	10.1136/neurintsurg-2021-018222
Abstrakt:	Background: There is considerable overlap of contributors to cardiovascular disease and the development of age-related macular degeneration (AMD). Compromised ocular microcirculation due to aging and vascular disease contribute to retinal dysfunction and vision loss. Decreased choroidal perfusion is evident in eyes with dry AMD and is thought to play a role in retinal pigment epithelial dysfunction, the rate of development of geographic atrophy, and the development of neovascularization. The aim of the study was to demonstrate that AMD is correlated with a compromised blood flow in the ocular pathway and show OA angioplasty as a potential treatment of late-stage AMD. Methods: Based on the potential for the ophthalmic artery (OA) to be an anatomical target for the treatment of AMD as outlined above, five patients were found to be eligible for compassionate use treatment, presenting clinically significant late-stage AMD with profound vision loss in one or both eyes, and are included in this retrospective study. Results: OA narrowing, or significant calcium burden at the ophthalmic segment of the internal carotid artery compromising the origin of the OA was confirmed in all cases. Subsequent OA cannulation was achieved in all patients with some difficulty. Subjective patient reports indicated that all patients perceived a benefit following the procedure; however, improved postoperative visual acuity did not confirm that perceived benefit for one of the patients. Conclusions: Feasibility and safety of the OA angioplasty were demonstrated, and a benefit perceived in five patients with profound vision loss and a desire to achieve improved quality of life. A clinical trial with controlled schedule, imaging, and methodologies is needed to confirm these results. Competing Interests: Competing interests: PNL: consultant for OcuDyne, Phenox, Medtronic, grant or contract from Philips with institution; TZ: consultant for OcuDyne; MC: consultant for OcuDyne. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu